This is a working overview of phase 2 trial, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-10. Anything still debated is marked as such rather than presented as settled.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
=== Mammography === Molybdenum targets are used in mammography because they produce X-rays in the energy range of 17–20 keV, which is optimal for imaging soft tissues like the breast. The characteristic X-rays emitted from molybdenum provide high contrast between different types of tissues, allowing for the effective visualization of microcalcifications and other subtle abnormalities in breast tissue. This energy range also minimizes radiation dose while maximizing image quality, making molybdenum targets particularly suitable for breast cancer screening.
During the three years spanning from 1969 to 1972, a total of 20,533 Americans had been killed in Vietnam, together with about 107,000 ARVN soldiers, and, as the American historian A.J. Langguth noted: "...perhaps five time that number of North Vietnamese and Vietcong troops. Civilian casualties were impossible to estimate. They may have run to a million men, women and children".
=== Blood glucose === Postprandial blood glucose levels become lower after consumption of a meal containing β-glucan as a result of increased gut viscosity, which delays gastric emptying and lengthens travel through the small intestine. In one review, the net decrease in blood glucose absorption reduced postprandial blood insulin concentrations, improving insulin sensitivity. A 2021 meta-analysis of clinical trials concluded that oat beta-glucan with molecular weights greater than 300 kg/mol reduced incremental area-under-the-curve by 23%, peak blood glucose by 28%, and insulin by 22% in a dose-responsive fashion, with similar results in participants with or without diabetes. Diabetic people who increased their daily consumption of beta-glucans by more than 3 grams per day for months also lost body weight.
=== Disaster recovery === Water damage resulting from flooding can result in shrinking, distortion, or staining of plant materials. Unforeseen disasters can occur at any time and disaster recovery planning and materials for herbaria are similar to museums and libraries. Little can be done with burnt specimens and fragmented specimens except to preserve and protect what is left intact. The damage most likely to occur is water damage through natural or man-made flooding, such as roof leakage or fire sprinkler malfunction. Damaged or waterlogged specimens are frozen to delay deterioration and prevent a fungal attack, which gives curators time to evaluate the situation and decide how best to approach the problem.
The Somali Armed Forces (SAF) are the military forces of the Federal Republic of Somalia. Headed by the President as Commander in Chief, they are constitutionally mandated to ensure the nation's sovereignty, independence and territorial integrity. The SAF was initially made up of the Army, Navy, Air Force, Police Force and the National Security Service. In the post-independence period, it grew to become among the larger militaries on the continent. The subsequent outbreak of the civil war in 1991 led to the disbandment of the Somali National Army. In 2004, the gradual process of reconstituting the military was put in motion with the establishment of the Transitional Federal Government (TFG). The Somali Armed Forces are now overseen by the Ministry of Defence of the Federal Government of Somalia, formed in mid-2012. In January 2013, the Somali federal government also reopened the national intelligence service in Mogadishu, renaming the agency the National Intelligence and Security Agency (NISA). The Somaliland and Puntland regional governments maintain their own security and police forces.
Sources: en.wikipedia.org
In 2010, Arby's opened a restaurant at Ft. Bliss, their first location at an American military base under a deal that the Wendy's/Arby's Group had signed with the Army and Air Force Exchange Service to open restaurants at bases both in the United States and overseas. Only American military personnel and some of their guests can patronize the Arby's locations situated on the military bases and operated by the Post Exchange. There were two different attempts to operate franchises in the United Kingdom. GSR Restaurant Group opened their first Arby's franchise location in London in 1992 followed by a second location the following year in Glasgow. These were also the first locations to open in Europe, but both were forced to close by 1994. In 2001, Barown Restaurants opened two Arby's franchise locations in Southampton, Hampshire, and Sutton, London, but both were forced to close after operating for a few months. On June 13, 2011, Wendy's/Arby's Group Inc. announced that it would sell the majority of its Arby's chain to Roark Capital Group while maintaining an 18.5% stake in the company. At the time of the sale, Arby's was experiencing an operating loss for the year of $35 million with 350 Arby's franchisees more than 60 days late in royalty payments and 74 low performing franchised units and 96 company-owned units forced to close. Despite its cash flow problem, Arby's also reported that it had six months of sales growth at established stores in the United States which it had attributed to its new turnaround plan that it had recently launched.
On average, the temperature of the ocean surface in the tropical East Pacific is roughly 8–10 °C (14–18 °F) cooler than in the tropical West Pacific. The sea surface temperature (SST) of the West Pacific northeast of Australia averages around 28–30 °C (82–86 °F). SSTs in the East Pacific off the western coast of South America are closer to 20 °C (68 °F). Strong trade winds near the equator drive water away from the East Pacific and into the West Pacific. This water is slowly warmed by the Sun as it moves west along the equator, the wind stress acting on the ocean surface being balanced by a sea surface slope. One result of this is that sea levels near Indonesia are typically around 0.5 m (1.5 ft) higher than that near Peru. The warm surface waters collect in the western Pacific, with the result that the thermocline, the transitional zone between the warmer waters near the ocean surface and the cooler waters of the deep ocean, lies much deeper in the western Pacific, where it has an average depth of around 140 m (450 ft) compared to around 30 m (90 ft) in the East Pacific. At depth, the sloping surface thermocline helps reduce the east–west pressure difference due to the sea level slope, but below the thermocline, the pressure difference is still enough to drive the eastward flowing cold equatorial undercurrent. The cooler deep ocean water replaces the outgoing surface waters in the East Pacific, rising to the ocean surface in a process called upwelling.
129I beta-decays to 129Xe with a half-life of 16.14±0.12 million years. The iodine-xenon chronometer is an isochron technique. Samples are exposed to neutrons in a nuclear reactor. This converts the only stable isotope of iodine (127I) into 128Xe via neutron capture followed by beta decay (of 128I). After irradiation, samples are heated in a series of steps and the xenon isotopic signature of the gas evolved in each step is analysed. When a consistent 129Xe/128Xe ratio is observed across several consecutive temperature steps, it can be interpreted as corresponding to a time at which the sample stopped losing xenon. Samples of a meteorite called Shallowater are usually included in the irradiation to monitor the conversion efficiency from 127I to 128Xe. The difference between the measured 129Xe/128Xe ratios of the sample and Shallowater then corresponds to the different ratios of 129I/127I when they each stopped losing xenon. This in turn corresponds to a difference in age of closure in the early solar system.
=== Pregnancy and newborns === Antidepressants, including SSRIs, can cross the placenta and have the potential to affect the fetus and newborn, including an increased chance of miscarriage, presenting a dilemma for pregnant women to decide whether to continue to take antidepressants at all, or if they do, considering if tapering and discontinuing during pregnancy could have a protective effect for the newborn. Neonatal withdrawal syndrome was first noticed in 1973 in newborns of mothers taking antidepressants; symptoms in the infant include irritability, rapid breathing, hypothermia, and blood sugar problems. The symptoms usually develop from birth to days after delivery and usually resolve within days or weeks of delivery.
== New York Giants == The New York Giants Fearsome Foursome consisting of ends Andy Robustelli and Jim Katcavage, and tackles Rosey Grier and Dick Modzelewski, first played together on the Giants 1956 NFL Championship Team. They were considered pioneers in inaugurating a defensive era in professional football. The Giants' Fearsome Foursome broke up as a group before the start of the 1963 season, when the Giants traded Grier to the Los Angeles Rams for John LoVetere. Other than during Grier's Army service in 1957, and a period of injury for Katcavage at the end of the 1960 season, the four played together in every minute of every game from 1956 to 1962. Robustelli is in the Pro Football Hall of Fame. In addition to winning the championship in 1956, the Giants went to four other NFL championship games, losing to the Baltimore Colts in 1958 (known as "the Greatest Game Ever Played"), and 1959 and the Green Bay Packers in 1961 and 1962. They were "largely responsible" for the Giants' success during these years. In the 1957 season the New York Daily News, a major New York city tabloid, ran an article and sketches of the New York Giants' line consisting of ends Andy Robustelli and Jim Katcavage, and tackles Rosey Grier and Dick Modzelewski and a headline that read "A Fearsome Foursome." They were known as the Fearsome Foursome by at least 1959, supported by an actual photograph of the four.
Sources: en.wikipedia.org
Several small-scale studies involving 15 or fewer test subjects conducted in the 1950s and 1960s reported that adrenochrome triggered psychotic reactions such as thought disorder and derealization. In 1954, researchers Abram Hoffer and Humphry Osmond claimed that adrenochrome is a neurotoxic, psychotomimetic substance and may play a role in schizophrenia and other mental illnesses. In what Hoffer called the "adrenochrome hypothesis", he and Osmond in 1967 speculated that megadoses of vitamin C and niacin could cure schizophrenia by reducing brain adrenochrome. The treatment of schizophrenia with such potent anti-oxidants is controversial. In 1973, the American Psychiatric Association reported methodological flaws in Hoffer's work on niacin as a schizophrenia treatment and referred to follow-up studies that did not confirm any benefits of the treatment. Multiple additional studies in the United States, Canada, and Australia similarly failed to find benefits of megavitamin therapy to treat schizophrenia. The adrenochrome theory of schizophrenia waned, despite some evidence that it may be psychotomimetic, as adrenochrome was not detectable in people with schizophrenia. In the early 2000s, interest was renewed by the discovery that adrenochrome may be produced normally as an intermediate in the formation of neuromelanin. This finding may be significant because adrenochrome is detoxified at least partially by glutathione-S-transferase. Some studies have found genetic defects in the gene for this enzyme. Adrenochrome is also believed to have cardiotoxic properties.
Nicotinamide riboside (NR, SR647) is a pyridine-nucleoside and a form of vitamin B3. It functions as a precursor to nicotinamide adenine dinucleotide, or NAD, through a two-step and a three-step pathway.
== Research and Discoveries == Strahl is a pioneer in the field of epigenetics, with contributions to the study of Chromatin biology. As a postdoctoral fellow in C. David Allis’ laboratory, helped to establish the identity of the first lysine and arginine histone methyltransferases and how they contribute to transcriptional activation and heterochromatin formation. Some examples include the discovery of the first histone methyltransferases that target lysine 4 (Set1), lysine 9 (SUV39H1), and lysine 36 of histone H3 (Set2/SETD2) and arginine 3 of histone H4 (PRMT1). Strahl also helped to develop the first antibodies for methylated histones in the Allis laboratory. In 2000, Strahl and Allis put forward the idea of the “histone code hypothesis”, which aimed to explain how multiple histone modifications function together to control chromatin structure and function. The early years of the Strahl laboratory, research focused on the roles of histone methylation and histone ubiquitylation in gene transcription. He linked histone H2B ubiquitylation to the regulation of H3 lysine 79 methylation and in transcriptional elongation and determined how H3 lysine 36 methylation is coupled to RNA Polymerase II and repressive chromatin during transcription elongation. His group also defined the key roles of several histone chaperones (e.g., Spt6) that function in transcription In more recent years, Strahl turned his attention to how chromatin-associated proteins engage histones and their modifications.
The elements listed below as "Essential in humans" are those listed by the US Food and Drug Administration as essential nutrients, as well as six additional elements: oxygen, carbon, hydrogen, and nitrogen (the fundamental building blocks of life on Earth), sulfur (essential to all cells) and cobalt (a necessary component of vitamin B12). Elements listed as "Possibly" or "Probably" essential are those cited by the US National Research Council as beneficial to human health and possibly or probably essential.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.